• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconAlzheimer's

Alzheimer's

Page 5 of 8
Le village Alzheimer
Health
Alzheimer’s villages could be the answer to the rising cases—and cost—of dementia
By Sophie MellorOctober 8, 2021
Biogen aduhelm aducanumab Alzheimer's doctor disapproval
Newsletters
The never ending Biogen Alzheimer’s drug saga delivers yet another twist
By Sy MukherjeeJuly 8, 2021
Biogen aduhelm aducanumab Alzheimer's doctor disapproval
Health
Biogen makes a drastic move, as doctors refuse to prescribe its controversial Alzheimer’s drug
By Sy MukherjeeJuly 8, 2021
The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019.
Health
Biogen won its controversial Alzheimer’s drug approval. Which drugmakers will see the next big win?
By Sy MukherjeeJune 9, 2021
The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019.
Health
FDA approves Biogen’s controversial Alzheimer’s drug in historic decision
By Sy MukherjeeJune 7, 2021
FDA Biogen Alzheimer's Janet Woodcock
Health
President Biden still hasn’t appointed a permanent FDA commissioner. That has big implications for upcoming drug approvals
By Sy MukherjeeMay 25, 2021
Alzheimer's drug week
Newsletters
A week about Alzheimer’s drug development
By Sy MukherjeeMarch 18, 2021
Biogen Sangamo Alzheimers gene therapy
Newsletters
Biogen is doubling down on Alzheimer’s with a massive gene therapy deal
By Sy MukherjeeFebruary 28, 2020
Biogen Alzheimers Drug Data
Newsletters
The Broader Implications of Biogen’s Divisive Alzheimer’s Drug
By Sy MukherjeeDecember 5, 2019
Biogen Stock Alzheimer's Aducanumab
Newsletters
Biogen Stock Falls After Analyst Throws Cold Water on Its Alzheimer’s Drug Bet
By Sy MukherjeeDecember 2, 2019
Bill Gates Alzheimers Part the Cloud
Newsletters
Bill Gates Commits $10 Million More for Alzheimer’s Research to ‘Part the Cloud’
By Sy MukherjeeNovember 4, 2019
Biogen Alzheimers Aducanumab
Newsletters
Let’s Talk About Biogen’s Stunning Alzheimer’s Drug Reversal: Brainstorm Health
By Sy MukherjeeOctober 22, 2019
A logo of the Swiss pharmaceuticals gian
Health
Roche Reports Another Failure in Big Pharma’s Search for Alzheimer’s Treatment
By Lucas LaursenJanuary 30, 2019
A New Blood Test Could Detect Alzheimers 10 Years Earlier
Health
A New Blood Test Could Detect Alzheimers 10 Years Earlier
By Emily PriceJanuary 21, 2019
The Power of a Joint Venture
Magazine
The Power of a Joint Venture
By Clifton LeafJanuary 18, 2019
1...
  • 3
  • 4
  • 5
  • 6
  • 7
8
Most Popular
Middle East
The emerging deal to reopen the Strait of Hormuz reportedly recognizes Iran’s control—and the U.S. may have to accept itplaceholder alt text
By Jason MaAugust 7, 2026
Economy
How Scott Bessent used financial engineering to finance the $2 trillion deficit while leaving it untouched—and created a $1.45 trillion shortfallplaceholder alt text
By Eva RoytburgAugust 8, 2026
Real Estate
The tables have turned: Florida and Texas are the biggest losers in the housing market as Ohio emerges a surprise winnerplaceholder alt text
By Sydney LakeAugust 8, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.